• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Actavis Ray of Hope for Beleaguered Iceland


8 February, 2010.

Iceland's global generics company Actavis Group is offering some light relief to the country's ongoing economic woes by increasing the capacity of its manufacturing site in Hafnarfjordur by 50%, thus creating fifty new jobs.

Production on the new facility, which exports 95% of its products, is expected to start at the end of this year. After expansion the SOD-site's capacity will be about 1.5 billion tablets per year, depending on the mix of products.


Actavis currently employs around 570 people in Iceland (which has a population of only 320,000) and over 10,000 people worldwide.